HSBC Issues Positive Forecast for Pfizer (NYSE:PFE) Stock Price

Pfizer (NYSE:PFE) had its price objective increased by HSBC from $29.00 to $32.00 in a research note published on Tuesday morning,Benzinga reports. HSBC currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently commented on the stock. Barclays started coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.14.

Pfizer Stock Performance

Shares of PFE stock opened at $27.47 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a 50-day moving average of $26.57 and a 200-day moving average of $25.56. Pfizer has a one year low of $20.92 and a one year high of $27.94. The company has a market cap of $156.21 billion, a P/E ratio of 20.20 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the previous year, the company earned $0.63 earnings per share. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. Equities research analysts forecast that Pfizer will post 2.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PFE. Triad Wealth Partners LLC increased its position in shares of Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 386 shares during the period. ETF Store Inc. boosted its holdings in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares during the period. Mattern Wealth Management LLC grew its stake in Pfizer by 4.6% in the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after purchasing an additional 400 shares in the last quarter. Pines Wealth Management LLC increased its holdings in Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 400 shares during the period. Finally, Peak Asset Management LLC raised its position in Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after purchasing an additional 402 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported positive topline Phase 2 results for its next‑generation CDK4 inhibitor atirmociclib in HR+/HER2‑ metastatic breast cancer — the combo reduced risk of progression or death by ~40% versus control, positioning atirmociclib as a potential successor to Ibrance and a meaningful oncology revenue driver if confirmed in later trials. Pfizer Announces Positive Topline Phase 2 Results for Atirmociclib
• Positive Sentiment: Major media and wire outlets (Reuters/BusinessWire) highlighted the trial win and its magnitude (40% risk reduction), which is driving optimism around Pfizer’s oncology strategy and helps the stock’s re‑rating story. Reuters: Pfizer experimental breast cancer drug cuts risk
• Positive Sentiment: HSBC raised its price target to $32 and maintained a Buy rating, giving institutional support and signaling ~16% upside to analysts’ consensus targets — a catalyst for near‑term buying. Benzinga: HSBC raises Pfizer PT
• Positive Sentiment: Competitive dynamics improved after a rival (Bicycle) scaled back a Padcev challenger, reducing near‑term competitive pressure on Pfizer’s fast‑selling bladder cancer drug. That lowers some downside risk to future sales. BioPharmaDive: Bicycle layoffs, Padcev challenger deprioritized
• Neutral Sentiment: Jim Cramer and other commentators noted Pfizer’s sizable pipeline (retail interest), which can boost retail flows but doesn’t change fundamentals absent confirmatory Phase 3 data or regulatory actions. Yahoo: Jim Cramer on Pfizer pipeline
• Neutral Sentiment: Coverage and attention pieces (Zacks, IP Group mentions) point to rising investor focus and deal flow benefits (e.g., prior Metsera deal), but these are incremental until monetized or reflected in guidance. Zacks: Pfizer attracting attention
• Negative Sentiment: Longer‑term risk reminder: analysts and commentators caution that Pfizer still faces revenue pressure from loss of COVID exclusivity and other patent cliffs — positive trial news helps re‑rate but does not eliminate those macro risks. The Motley Fool: Key risks for Pfizer

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.